Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep 1;49(9):851-854.
doi: 10.1097/DSS.0000000000003866. Epub 2023 Jun 22.

Intradermal Delivery of Alopecia Therapeutics: Current State and Future Prospects

Lina Alhanshali  1 , Michael Buontempo  2 , Daniela Majerson  3 , Jerry Shapiro  4 , Kristen Lo Sicco  4
Affiliations

Intradermal Delivery of Alopecia Therapeutics: Current State and Future Prospects

Lina Alhanshali et al. Dermatol Surg. .

Abstract

Background: Mesotherapy, a technique of transdermal microinjections of specific preparations, is increasingly used in fields such as dermatology and specifically for alopecia treatment. Its popularity stems from its ability to deliver drugs in a targeted manner while minimizing systemic side effects.

Objective: To assess and review current knowledge regarding the use of mesotherapy to deliver alopecia medications and highlight future directions for research.

Materials and methods: The authors used research databases including PubMed and Google Scholar to identify current literature on mesotherapy and alopecia. The following search terms were used among other terms: "Mesotherapy" or "Intradermal" AND "Alopecia".

Results: Recent studies are promising for the intradermal delivery of dutasteride and minoxidil in the treatment of androgenetic alopecia.

Conclusion: Although limitations exist with dutasteride and minoxidil therapies, further research regarding the preparation, delivery, and maintenance of these drugs is warranted as mesotherapy could establish this technique as a safe, effective, and viable treatment option for androgenetic alopecia.

PubMed Disclaimer

References

    1. Pistor M. What is mesotherapy? [article in French]. Chir Dent Fr 1976;46:59–60.
    1. Otberg N, Finner AM, Shapiro J. Androgenetic alopecia. Endocrinol Metab Clin North America 2007;36:379–98.
    1. Vañó-Galván S, Pirmez R, Hermosa-Gelbard A, Moreno-Arrones ÓM, et al. Safety of low-dose oral minoxidil for hair loss: a multicenter study of 1404 patients. J Am Acad Dermatol 2021;84:1644–51.
    1. Hirshburg JM, Kelsey PA, Therrien CA, Gavino AC, et al. Adverse effects and safety of 5-alpha reductase inhibitors (finasteride, dutasteride): a systematic review. J Clin Aesthet Dermatol 2016;9:56–62.
    1. Tang Z, Hu Y, Wang J, Fan Z, et al. Current application of mesotherapy in pattern hair loss: a systematic review. J Cosmet Dermatol 2022;21:4184–93.

LinkOut - more resources